한빛사 논문
Kye Il Jooa,1, Yeonsu Jeonga,1, Sung-Min Hwangb,1, Mincheol Shina, Jaeyun Leea, Garima Sharmac, Haena Leeb, Sin-Hyeog Imb,d,*, Hyung Joon Chaa,*
aDepartment of Chemical Engineering, Pohang University of Science and Technology, Pohang, 37673, Republic of Korea
bDivision of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology, Pohang, 37673, Republic of Korea
cImmunoBiome. Inc. POSTECH Biotech Center, Pohang 37673, Republic of Korea
dDepartment of Life Sciences, Pohang University of Science and Technology, Pohang, 37673, Republic of Korea
1These three authors contributed equally to this work.
*Corresponding author
Abstract
Despite the great promise of immune checkpoint blockade (ICB) therapy for cancer treatment, the currently available options for ICB treatment pose major clinical challenges, including the risk of severe systemic autoimmune responses. Here, we developed a novel localized delivery platform, immuno-bioglue (imuGlue), which is inspired by the intrinsic underwater adhesion properties of marine mussels and can allow the optimal retention of anti-PD-L1 drugs at tumor sites and the on-demand release of drugs in response to the tumor microenvironment. Using a triple-negative breast cancer and melanoma models, we found that imuGlue could significantly enhance anti-tumor efficacy by eliciting a robust T cell-mediated immune response while reducing systemic toxicity by preventing the rapid diffusion of anti-PD-L1 drugs into the systemic circulation and other tissues. It was also demonstrated that imuGlue could be successfully utilized for combination therapy with other immunomodulatory drugs to enhance the anti-tumor efficacy of ICB-based immunotherapy, demonstrating its versatility as a new treatment option for cancer immunotherapy.
Keywords : Immune checkpoint blockade; Mussel adhesive protein; Localized immunotherapy; Combination cancer immunotherapy; Anti-PD-L1
논문정보
TOP52020년 후보
관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기